Why Immutep Limited’s (IMMP) Stock Is Down 11.71%
As of Monday, September 14, Immutep Limited’s IMMP share price has dipped by 11.71%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Commentary & Analysis
Why Immutep Limited’s (IMMP) Stock Is Down 11.30%
As of Monday, September 14, Immutep Limited’s IMMP share price has dipped by 11.30%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immutep Limited’s (IMMP) Stock Is Down 5.07%
As of Friday, July 17, Immutep Limited’s IMMP share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Immutep Limited’s (IMMP) Stock Is Up 5.56%
As of Monday, July 13, Immutep Limited’s IMMP share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Why Immutep Limited’s (IMMP) Stock Is Down 5.12%
As of Wednesday, July 08, Immutep Limited’s IMMP share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $43.0 | $271.9 | 14% |
|
| Shares Out (Mil) | 1,018.6 | 54.2 | 94% |
|
| Institutional Ownership | 94.1% | 92.9% | 64% |
|
| Float (Mil) | 1,400.9 | 42.1 | 93% |
|
| Beta | 2.20 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 592 | 612 | 59% |
|
| Price Change (52-week) |
(82.7%) | 56.0% | 6% |
|
| Growth | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.6% | 13.1% | 92% |
|
| Net Income (5yr) | (19.6%) | (10.1%) | 20% |
|
| EPS (5yr) | 0.5% | 15.7% | 32 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $14 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($55) | ($43) | 15% |
|
| EPS (TTM) | ($0.037) | ($1.500) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $2 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $177 | 3% |
|
| Valuation | IMMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.44 | 2.67 | 90% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (361.3%) | 69.0% | 1% |
|
| Net Margin | (397.8%) | (71.5%) | 2% |
|
| ROA | (68.4%) | (47.4%) | 9% |
|
| ROE | (80.2%) | (54.6%) | 11% |
|
| Liabilities to Assets | 26.1% | 29.3% | 18% |
|
| F-Score | 3 | 3 | 18% |
|
Immutep Limited did not pass any screens on 9/22/2026.
